This article has been updated to include comments from WaferGen's conference call following the release of results.


NEW YORK (GenomeWeb) - WaferGen Biosystems reported after the close of the market Wednesday that its second quarter revenues fell 6 percent due to reduced SmartChip capital equipment sales.

For the three months ended June 30, the genetic analysis products maker reported total revenues of $1.6 million, compared to $1.7 million in Q2 2014 and short of the consensus analysts' estimate of $2.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.